# NanoString Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nanostring-technologies

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.nanostring.com/
- Total disclosed funding: $66M
- Latest round: Series E (Dec 3, 2012)
- Investors on record: 7

## About

Based in Washington, US, and founded in 2003 and led by CEO Brad Gray, NanoString Technologies, Inc. operates as a healthcare company providing life science tools for research, translational medicine and research applications, and in vitro diagnostics. In May 2024, Bruker Corporation fully acquired NanoString Technologies, Inc. from Patient Square Capital, DFJ, OVP Venture Partners, and many more. 

NanoString's product portfolio includes three main platforms such as the nCounter analysis system, GeoMx digital spatial profiler, and CosMx spatial molecular imager. The nCounter system offers rapid gene expression insights through 800-plex direct digital detection. The GeoMx DSP enables spatial profiling of transcriptomes and proteins in tissue samples. The CosMx SMI provides high-resolution, multiomic, spatial single-cell imaging, allowing for in-depth cell atlasing and biomarker discovery. In addition, the firm’s platforms support a wide range of research applications in oncology, immunology, neuroscience, and infectious diseases.

## Funding rounds

- Series E, Dec 3, 2012, $15M — Draper Fisher Jurvetson, GE Capital, Equity, OVP Venture Partners, BioMed Partners, Clarus Ventures, AllianceBernstein, Morgan Stanley Expansion Capital
- Series D, Nov 7, 2011, $20M — Draper Fisher Jurvetson, GE Capital, Equity, OVP Venture Partners, BioMed Partners, Clarus Ventures
- Series C, Jun 8, 2009, $14M — Draper Fisher Jurvetson, OVP Venture Partners, Clarus Ventures
- Series B, May 16, 2007, $9M — Draper Fisher Jurvetson, OVP Venture Partners
- Series B, Apr 27, 2005, $3.8M — Draper Fisher Jurvetson, OVP Venture Partners
- Series A, Aug 11, 2004, $4.3M — Draper Fisher Jurvetson, OVP Venture Partners

## Investors

- Draper Fisher Jurvetson (https://capitalatlas.ai/funds/draper-fisher-jurvetson) — Series A, Series B, Series C, Series D, Series E
- OVP Venture Partners (https://capitalatlas.ai/funds/ovp-venture-partners) — Series A, Series B, Series C, Series D, Series E
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series C, Series D, Series E
- GE Capital, Equity (https://capitalatlas.ai/funds/ge-capital-equity) — Series D, Series E
- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series D, Series E
- AllianceBernstein (https://capitalatlas.ai/funds/alliancebernstein) — Series E
- Morgan Stanley Expansion Capital (https://capitalatlas.ai/funds/morgan-stanley-expansion-capital) — Series E